The Inflation Reduction Act & Medicare Pricing for Drugs and Biologics

Matt Wetzel, Life Sciences Partner at Goodwin, conducted a webinar in April 2023 covering the latest updates on the Inflation Reduction Act and the law’s sweeping changes to how the government intends to pay for pharmaceuticals and biologics. The new Medicare price negotiation program, inflation-based rebates, and other changes to how Medicare covers and pays for drugs – including changes to prescription drug benefits for America’s seniors - will have an impact for many years to come. Matt provided an analysis of the Inflation Reduction Act’s requirements, the federal government’s ongoing implementation of the law, how drug companies are currently reacting, and what they can do to prepare for the Inflation Reduction Act’s full impact.

Copies of the webinar presentation materials are available here.

For a copy of Goodwin's IRA Summary Placemat, click here.

Click here for a link to an IRA panel featuring Matt and conducted by the UK BioIndustry Association.